scholarly journals Reply to: Effects of donor muscle and sex on graft function in living‐donor liver transplantation

2020 ◽  
Vol 20 (12) ◽  
pp. 3699-3700
Author(s):  
Yosuke Miyachi ◽  
Toshimi Kaido ◽  
Shinji Uemoto
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Graft Function ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Donor Muscle

scholarly journals Effects of donor muscle and sex on graft function in living‐donor liver transplantation

2020 ◽  
Vol 20 (12) ◽  
pp. 3697-3698 ◽  
Author(s):  
Takeshi Gocho ◽  
Kenei Furukawa ◽  
Hironori Shiozaki ◽  
Jungo Yasuda ◽  
Yoshihiro Shirai ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Graft Function ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Donor Muscle

scholarly journals A Lipidomics Study Reveals Lipid Signatures Associated with Early Allograft Dysfunction in Living Donor Liver Transplantation

2018 ◽  
Vol 8 (1) ◽  
pp. 30 ◽  
Author(s):  
Hsin-I Tsai ◽  
Chi-Jen Lo ◽  
Chih-Wen Zheng ◽  
Chao-Wei Lee ◽  
Wei-Chen Lee ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Graft Function ◽  
Resonance Spectroscopy ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Allograft Dysfunction ◽  
Latent Structures ◽  
Early Allograft Dysfunction

Liver transplantation has become the ultimate treatment for patients with end stage liver disease. However, early allograft dysfunction (EAD) has been associated with allograft loss or mortality after transplantation. We aim to utilize a metabolomic platform to identify novel biomarkers for more accurate correlation with EAD using blood samples collected from 51 recipients undergoing living donor liver transplantation (LDLT) by 1H-nuclear magnetic resonance spectroscopy (NMR) and liquid chromatography coupled with mass spectrometry (LC-MS). Principal component analysis (PCA) and orthogonal projection to latent structures-discriminant analysis (OPLS-DA) were used to search for a relationship between the metabolomic profiles and the presence of EAD.Cholesteryl esters (CEs), triacylglycerols (TGs), phosphatidylcholines (PCs) and lysophosphatidylcholine (lysoPC) were identified in association with EAD and a combination of cholesterol oleate, PC (16:0/16:0), and lysoPC (16:0) gave an optimal area under the curve (AUC) of 0.9487 and 0.7884 in the prediction of EAD and in-hospital mortality, respectively after LDLT. Such biomarkers may add as a potential clinical panel for the prediction of graft function and mortality after LDLT.

KICG value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation

2006 ◽  
Vol 12 (4) ◽  
pp. 605-613 ◽  
Author(s):  
Tomohide Hori ◽  
Taku Iida ◽  
Shintaro Yagi ◽  
Kentaro Taniguchi ◽  
Chiduru Yamamoto ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Real Time ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Graft Function ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals Simultaneous ABO-incompatible living-donor liver transplantation and splenectomy without plasma exchange in China: Two case reports

2017 ◽  
Vol 45 (6) ◽  
pp. 2146-2152 ◽  
Author(s):  
Guoyong Chen ◽  
Janjun Sun ◽  
Sidong Wei ◽  
Yongfeng Chen ◽  
Gaofeng Tang ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Case Reports ◽  
Graft Function ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Antibody Mediated Rejection ◽  
First Case ◽  
Life Saving

ABO-incompatible (ABO-i) living-donor liver transplantation (LDLT) is performed if an ABO-compatible graft cannot be obtained. However, a perfect desensitization protocol has not been established worldwide, especially for simultaneous ABO-i LDLT and splenectomy. We herein report two cases of ABO-i LDLT. To the best of our knowledge, this is the first case report of ABO-i LDLT in an adult patient in China. Splenectomy and T-cell-targeted immunosuppression (basiliximab) was used to overcome the blood group barrier in these recipients. The patients had good graft function without signs of antibody-mediated rejection throughout the 12-month follow-up. Thus, ABO-i LDLT with splenectomy is undoubtedly life-saving when an ABO-compatible graft cannot be obtained for patients in critical condition.

Sign in / Sign up

Export Citation Format

Share Document